Posts Tagged ‘TRIPS waiver’
Where things stand with the TRIPS waiver
The World Trade Organization is considering continuing to waive certain intellectual property rights on COVID-19 diagnostics and therapeutics, following a recent decision to do the same for vaccines.
Read MoreExpanding COVID IP waiver would harm small, medium enterprises, CSBA says
Every member of the Council of State Bioscience Associations signed a letter to President Joe Biden expressing serious concerns with the proposed expansion of IP protections for COVID technology.
Read MoreRep. Ross discusses immigration, IP, workforce and more with NCBIO members
Immigration reform, protection of intellectual property, the threat of antimicrobial resistance, workforce training and more were topics covered by Rep. Deborah Ross at an NCBIO legislative round table held Monday, Feb. 14, at the NC Biotechnology Center.
Read MoreLaura Gunter: Biotech policies should protect patients, innovation
Laura Gunter: Biotech policies should protect patients, innovation The ongoing response to the COVID-19 pandemic has highlighted the critical role of the North Carolina life sciences industry in battling our most serious public health threats. When faced with the threat of COVID-19, biotechnology companies — many based right here in North Carolina — answered the…
Read MoreBIO’s fall Congressional preview
The summer calm is grinding to a halt as members of Congress have returned to D.C. for what is sure to be a busy legislative sprint that could potentially impact all sectors of the biotech industry.
Read MoreBIO: Where things stand with TRIPS waiver
BIO: Where things stand with TRIPS waiver It’s been a while since we’ve talked about what’s going on at the WTO. Here’s the latest news—and why the proposed waiver of vaccine IP is still a bad idea. The status: The World Trade Organization is still considering a proposal backed by India and South Africa (and…
Read MoreVaccine patent waiver breaks faith with American companies, stifles innovation
Vaccine patent waiver breaks faith with American companies, stifles innovation NCBIO is extremely disappointed that the Biden administration has chosen to support waiving critical intellectual property protections for U.S. COVID-19 vaccines. This decision, known as a TRIPS waiver, breaks faith with American innovators, punishes the ingenuity of our life sciences industry and will delay the…
Read MoreBIO: Why the TRIPS waiver wouldn’t work
BIO President and CEO Dr. Michelle McMurry-Heath sent a letter April 19 to U.S. Trade Representative Ambassador Katherine Tai to explain why the WTO’s proposed “TRIPS waiver” would have global health and economic consequences as the pandemic rages on.
Read More